Cell banks keep living cells available for later work. Laboratories freeze cells at very low temperature. They then thaw those cells when a new experiment or production run begins. Recovery measures whether the bank still yields healthy, authentic cultures. Therefore, cryopreservation, thawing, and recovery form one controlled process.
Cryopreservation stops ice and biochemistry from destroying the cell. Water inside the cell can form crystals during slow cooling. Those crystals rupture membranes. In contrast, a cryoprotectant such as dimethyl sulfoxide (DMSO) or glycerol lowers the freezing point. It also reduces ice growth. Most mammalian protocols mix cells with 5–10 percent DMSO in serum-containing or defined medium. Next, technicians cool the suspension in a controlled-rate freezer or a Mr. Frosty–type container. A common target is about one degree Celsius per minute down to −80 °C. After that, vials move to liquid nitrogen vapor or liquid phase. Storage below −150 °C keeps molecular motion near a standstill.
Cell banks exist at more than one level. A master cell bank (MCB) is the primary, fully tested stock. A working cell bank (WCB) is expanded from the MCB for routine use. This two-tier system protects the original line. It also limits passage number. Moreover, each bank needs identity tests. Short tandem repeat (STR) profiling confirms human lines. Mycoplasma testing, sterility checks, and viability counts belong in the same file. As a result, a bank is not only a freezer box. It is a documented product.
Thawing must be fast and gentle. Slow thawing allows ice to recrystallize. That process damages membranes again. Therefore, staff place the vial in a 37 °C water bath until a small ice core remains. They then dilute the cells into prewarmed medium. Dilution lowers the DMSO concentration. DMSO is toxic at room temperature and at 37 °C. Consequently, operators remove the cryoprotectant by centrifugation or by a large-volume wash. They plate the pellet at a density that supports recovery. Too few cells delay growth. Too many cells create stress and waste.
Recovery is more than a trypan-blue number. Immediate post-thaw viability can look acceptable. However, many cells die over the next 24 hours. Attachment, doubling time, and morphology matter more. Some lines need a recovery passage before any assay. Stem cells and primary cells often show this lag. In addition, freeze–thaw cycles can select hardy subclones. Phenotype then drifts. Researchers should therefore compare recovered cells with the pre-freeze profile. Growth curves, marker expression, and contamination screens complete the check.
Several errors reduce bank quality. Over-confluent cultures enter freeze-down in poor condition. High passage number already carries mutations. Incomplete mixing leaves DMSO gradients inside the vial. Meanwhile, frost on vial caps invites contamination at thaw. Warm vials that sit on the bench lose viability quickly. Repeated freeze–thaw of the same vial is worse. Each cycle kills more cells. Good practice uses one vial once.
Documentation ties the process together. Records should list passage, density, cryoprotectant lot, cooling method, storage location, and test results. A unique vial ID prevents mix-ups. Backup storage in a second tank reduces catastrophic loss. Furthermore, emergency plans matter when nitrogen supply fails. Alarms and spare capacity protect years of work.
In short, cryopreservation preserves a defined cell population. Controlled cooling and a cryoprotectant limit ice injury. Rapid thawing and prompt dilution limit solvent toxicity. Recovery testing then proves that the bank still represents the intended line. Master and working banks, identity assays, and strict single-use vials keep the system reliable. Careful technique at each step protects both science and downstream products.
CMP Bio World 